Review articlePublished 22 Feb 2017
Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Since pembrolizumab (Keytruda®) was approved for advanced melanoma in September 2014, multiple PD-1 blockade agents have been explored in other malignancies. Emerging clinical data has demonstrated durable clinical activity and safety of PD-1/L1 blockade agents in diverse cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma, and head and neck cancer. Thus, PD-1/L1 blockade agents have led to a paradigm shift in cancer therapy. In this review, current indications of PD-1 blockade agents in advanced solid malignancies will be discussed.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biomedical Sciences
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Dae Won Kim”
- BylineArticles whose byline prints “Marc Uemura”
- BylineArticles whose byline prints “Adi Diab”
